2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1500

The Multi-Biomarker Disease Activity Score Tracks Response to Rituximab Treatment in Rheumatoid Arthritis Patients
Abstract Number: 1501

Assessment of Treatment Response Using the Multi-Biomarker Disease Activity Score in Rheumatoid Arthritis Patients Initiating Methotrexate
Abstract Number: 1502

Predicting Response to Methotrexate Therapy in New-Onset RA: No Value of Adding Protein Biomarkers to Clinical Predictors
Abstract Number: 1503

Rheumatoid Factor Positivity Is Related with Higher Discontinuation Rate of Tumor Necrosis Factor Inhibitor Therapy Due to Adverse Event and Insufficient Response in Rheumatoid Arthritis: A Multiple Imputation Method for COX Proportional Hazard Model
Abstract Number: 1504

Utility of Serial ACPA Measurements in Rheumatoid Arthritis: Results of a Prospective Cohort Study
Abstract Number: 1505

The Point-of-Care Ichroma Anti-CCP Test Showed a Competitive Measurement Accuracy, in Comparison to the Conventional Automated Tests
Abstract Number: 1506

Synovial Tissue Histopathology Findings in EARLY RA. Is It Usefull? Analysis of the Belgian CAP48 Cohort
Abstract Number: 1507

Predictors of Fatigue and Persistent Fatigue in Early Rheumatoid Arthritis: A Longitudinal Observational Study
Abstract Number: 1508

Relationship between BMI and Lower Limb Dysfunction in Japanese Female Patients with Rheumatoid Arthritis (the data from NinJa registry)
Abstract Number: 1509

Associations between Perceived Stress and Joint Signs in an Anti-Cyclic Citrullinated Peptide Antibody Positive at-Risk Population
Abstract Number: 1510

Depression Is a Major Driver of Functional Capacity in Patients with Rheumatoid Arthritis Regardless of Disease Activity
Abstract Number: 1511

The Relationship between Lipid Profile Changes and Inflammation across the Phase 3 Sarilumab Rheumatoid Arthritis (RA) Developmental Program
Abstract Number: 1512

Reduction in Power Doppler Ultrasound Score with Tocilizumab Treatment Associates with Improvement in the Protective Profile of HDL in Patients with Rheumatoid Arthritis
Abstract Number: 1513

Efficacy of Etanercept By Body Mass Index in Women and Men with Rheumatoid Arthritis: A Post Hoc Analysis of Three Randomized Trials
Abstract Number: 1514

Impact of Comorbidity Burden and Obesity on the Effectiveness of Tocilizumab in Patients with Rheumatoid Arthritis

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].